Advertisement

Advertisement

CGTX Stock Latest News

Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications

RatingsCognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications

Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress

PremiumCompany Announcements

Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress

11d ago

Cognition Therapeutics’ zervimesine shows eficacy in dementia trial

PremiumThe Fly

Cognition Therapeutics’ zervimesine shows eficacy in dementia trial

20d ago

Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating

PremiumRatings

Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating

1M ago

Cognition Therapeutics Advances Zervimesine for DLB Psychosis

PremiumCompany Announcements

Cognition Therapeutics Advances Zervimesine for DLB Psychosis

1M ago

Cognition Therapeutics announces plans to advance development of zervimesine

PremiumThe FlyCognition Therapeutics announces plans to advance development of zervimesine

1M ago

Cognition Therapeutics extends duration of EAP for zervimesine

The Fly

Cognition Therapeutics extends duration of EAP for zervimesine

2M ago

Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial

Company Announcements

Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial

2M ago

Cognition Therapeutics completes Type C meeting with FDA for zervimesine

PremiumThe Fly

Cognition Therapeutics completes Type C meeting with FDA for zervimesine

2M ago

Cognition publishes Phase 2 results on Zervimesine

PremiumThe Fly

Cognition publishes Phase 2 results on Zervimesine

3M ago

Cognition Therapeutics Launches New $75M ATM Offering

PremiumCompany Announcements

Cognition Therapeutics Launches New $75M ATM Offering

4M ago

Cognition Therapeutics files $300M mixed securities shelf

PremiumThe Fly

Cognition Therapeutics files $300M mixed securities shelf

4M ago

Cognition Therapeutics’ Promising Advances in Dementia Treatment Justify Buy Rating

PremiumRatingsCognition Therapeutics’ Promising Advances in Dementia Treatment Justify Buy Rating

4M ago

Cognition reaches full enrollment in expanded access program for CT1812

The Fly

Cognition reaches full enrollment in expanded access program for CT1812

4M ago

Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s

The Fly

Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s

4M ago

Cognition Therapeutics price target raisd to $3 from $2 at B. Riley

PremiumThe Fly

Cognition Therapeutics price target raisd to $3 from $2 at B. Riley

5M ago

Cognition Therapeutics completes enrollment in Phase 2 study of Zervimesine

PremiumThe Fly

Cognition Therapeutics completes enrollment in Phase 2 study of Zervimesine

5M ago

Optimistic Buy Rating for Cognition Therapeutics Amid Promising Developments in Alzheimer’s and Dementia Treatment

PremiumRatings

Optimistic Buy Rating for Cognition Therapeutics Amid Promising Developments in Alzheimer’s and Dementia Treatment

5M ago

Cognition Therapeutics Advances Alzheimer’s Drug Development

PremiumCompany Announcements

Cognition Therapeutics Advances Alzheimer’s Drug Development

5M ago

Cognition Therapeutics reports Q3 EPS (6c), consensus (9c)

PremiumThe FlyCognition Therapeutics reports Q3 EPS (6c), consensus (9c)

5M ago

Cognition Therapeutics Advances Zervimesine to Phase 3 Trials

Company Announcements

Cognition Therapeutics Advances Zervimesine to Phase 3 Trials

7M ago

Cognition Therapeutics announces Phase 2 ‘START’ study reached 75% enrollment

The Fly

Cognition Therapeutics announces Phase 2 ‘START’ study reached 75% enrollment

7M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >